![Transparency Market Researchが調査・発行した産業分析レポートです。世界の慢性特発性便秘症治療市場2020年ｰ2030年：医薬品分類別（セロトニン-4 [5-Ht4]受容体作動薬、グアニル酸シクラーゼ-C作動薬、下剤、覚醒剤、その他）、投与経路別、流通チャネル別 / Chronic Idiopathic Constipation Treatment Market (Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, and Others; Route of Administration: Oral and Rectal; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030(CIC) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2030 / MRC2103G018資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/99x123xreport-contents-91.gif.pagespeed.ic.cYgo-ZH9PJ.jpg) | • レポートコード：MRC2103G018 • 出版社/出版日：Transparency Market Research / 2020年12月15日 • レポート形態：英文、PDF、295ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide Licence | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、世界の慢性特発性便秘症治療市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、医薬品分類別（セロトニン-4 [5-Ht4]受容体作動薬、グアニル酸シクラーゼ-C作動薬、下剤、覚醒剤、その他）分析、投与経路別分析、流通チャネル別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・慢性特発性便秘症治療の世界市場規模：医薬品分類別（セロトニン-4 [5-Ht4]受容体作動薬、グアニル酸シクラーゼ-C作動薬、下剤、覚醒剤、その他） ・慢性特発性便秘症治療の世界市場規模：投与経路別 ・慢性特発性便秘症治療の世界市場規模：流通チャネル別 ・慢性特発性便秘症治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Chronic Idiopathic Constipation Treatment Market – Scope of the Report
TMR’s report on the global chronic idiopathic constipation treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global chronic idiopathic constipation treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic idiopathic constipation treatment market during the forecast period.
The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global chronic idiopathic constipation treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global chronic idiopathic constipation treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic idiopathic constipation treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic idiopathic constipation treatment market.
The report delves into the competition landscape of the global chronic idiopathic constipation treatment market. Key players operating in the global chronic idiopathic constipation treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global chronic idiopathic constipation treatment market that have been profiled in this report.
Key Questions Answered in Chronic Idiopathic Constipation Treatment Market Report
What is the scope of growth for product companies in the global chronic idiopathic constipation treatment market?
What will be the Y-o-Y growth of the global chronic idiopathic constipation treatment market between 2020 and 2030?
What is the influence of changing trends in technologies on the global chronic idiopathic constipation treatment market?
Will North America continue to be the most profitable market for chronic idiopathic constipation treatment?
Which factors are anticipated to hamper the global chronic idiopathic constipation treatment market during the forecast period?
Which are the leading companies in the global chronic idiopathic constipation treatment market?
Research Methodology
A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global chronic idiopathic constipation treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary research sources referred to by analysts during the production of the global chronic idiopathic constipation treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the chronic idiopathic constipation treatment market as primary methods.
These primary research respondents have provided exclusive information during interviews, which serves as a validation from the chronic idiopathic constipation treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global chronic idiopathic constipation treatment market with accuracy. The study also uses the top-down approach to assess the revenues of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global chronic idiopathic constipation treatment more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Idiopathic Constipation Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.3. Diseases Prevalence by Global/Sub-region
5.4. Key Developments
6. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
6.3.1. Serotonin-4 (5-Ht4) Receptor Agonist
6.3.1.1. Prucalopride
6.3.1.2. Others
6.3.2. Guanylate Cyclase-C Agonist
6.3.2.1. Plecanatide
6.3.2.2. Linaclotide
6.3.3. Laxatives
6.3.3.1. Sodium Picosulphate
6.3.3.2. Polycarbophil
6.3.3.3. Others
6.3.4. Stimulants
6.3.4.1. Bisacodyl
6.3.4.2. Senokot
6.3.4.3. Others
6.3.5. Others
6.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class
7. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
7.3.1. Oral
7.3.2. Rectal
7.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration
8. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel
9. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Region
10. North America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
10.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
10.2.1.1. Prucalopride
10.2.1.2. Others
10.2.2. Guanylate Cyclase-C Agonist
10.2.2.1. Plecanatide
10.2.2.2. Linaclotide
10.2.3. Laxatives
10.2.3.1. Sodium Picosulphate
10.2.3.2. Polycarbophil
10.2.3.3. Others
10.2.4. Stimulants
10.2.4.1. Bisacodyl
10.2.4.2. Senokot
10.2.4.3. Others
10.2.5. Others
10.3. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
10.3.1. Oral
10.3.2. Rectal
10.4. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
10.5.1. U.S.
10.5.2. Canada
10.6. North America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
11.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
11.2.1.1. Prucalopride
11.2.1.2. Others
11.2.2. Guanylate Cyclase-C Agonist
11.2.2.1. Plecanatide
11.2.2.2. Linaclotide
11.2.3. Laxatives
11.2.3.1. Sodium Picosulphate
11.2.3.2. Polycarbophil
11.2.3.3. Others
11.2.4. Stimulants
11.2.4.1. Bisacodyl
11.2.4.2. Senokot
11.2.4.3. Others
11.2.5. Others
11.3. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
11.3.1. Oral
11.3.2. Rectal
11.4. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
12.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
12.2.1.1. Prucalopride
12.2.1.2. Others
12.2.2. Guanylate Cyclase-C Agonist
12.2.2.1. Plecanatide
12.2.2.2. Linaclotide
12.2.3. Laxatives
12.2.3.1. Sodium Picosulphate
12.2.3.2. Polycarbophil
12.2.3.3. Others
12.2.4. Stimulants
12.2.4.1. Bisacodyl
12.2.4.2. Senokot
12.2.4.3. Others
12.2.5. Others
12.3. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
12.3.1. Oral
12.3.2. Rectal
12.4. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
13.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
13.2.1.1. Prucalopride
13.2.1.2. Others
13.2.2. Guanylate Cyclase-C Agonist
13.2.2.1. Plecanatide
13.2.2.2. Linaclotide
13.2.3. Laxatives
13.2.3.1. Sodium Picosulphate
13.2.3.2. Polycarbophil
13.2.3.3. Others
13.2.4. Stimulants
13.2.4.1. Bisacodyl
13.2.4.2. Senokot
13.2.4.3. Others
13.2.5. Others
13.3. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
13.3.1. Oral
13.3.2. Rectal
13.4. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
14.2.1. Serotonin-4 (5-Ht4) Receptor Agonist
14.2.1.1. Prucalopride
14.2.1.2. Others
14.2.2. Guanylate Cyclase-C Agonist
14.2.2.1. Plecanatide
14.2.2.2. Linaclotide
14.2.3. Laxatives
14.2.3.1. Sodium Picosulphate
14.2.3.2. Polycarbophil
14.2.3.3. Others
14.2.4. Stimulants
14.2.4.1. Bisacodyl
14.2.4.2. Senokot
14.2.4.3. Others
14.2.5. Others
14.3. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
14.3.1. Oral
14.3.2. Rectal
14.4. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis/Ranking By Company (2019)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Allergan
15.3.2.1. Company Overview
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Bausch Health
15.3.3.1. Company Overview
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Sanofi
15.3.4.1. Company Overview
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Takeda Pharmaceutical Company
15.3.5.1. Company Overview
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. SEBELA PHARMACEUTICALS
15.3.6.1. Company Overview
15.3.6.2. Growth Strategies
15.3.6.3. SWOT Analysis
15.3.7. Ironwood Pharmaceuticals, Inc.
15.3.7.1. Company Overview
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Albireo Pharma, Inc.
15.3.8.1. Company Overview
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)
15.3.9.1. Company Overview
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
15.3.10.1. Company Overview
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
Table 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 02: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 03: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 04: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 05: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 06: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 07: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 09: North America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 10: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 11: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 12: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 13: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 14: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 15: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 16: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 17: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 18: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 19: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 20: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 21: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 22: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 23: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 24: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 27: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 28: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 29: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 30: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 31: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 32: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 33: Latin America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 34: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 35: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 36: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 37: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 38: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 39: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 40: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 41: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 42: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 43: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030
Table 44: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030
Table 45: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030
Table 46: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030
Table 47: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 48: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030